### **Prior Publication:**

The *Journal of Atherosclerosis and Thrombosis*, *JAT*, is the official publication of the Japan Atherosclerosis Society (JAS) and the Asian-Pacific Society of Atherosclerosis and Vascular Disease (APSAVD). Contribution from non-members is also acceptable.

JAT publishes articles focused on all aspects of research on atherosclerosis, vascular biology, thrombosis, lipid and metabolism.

The editors of JAT aim to publish original contributions. Therefore, for Original Article, Case Report, Editorial and Correspondence, JAT will not publish articles in which a significant portion of the data, either in the form of figures or tables, has been published or submitted for publication elsewhere. JAT requires the authors' state in their cover letter that no data similar to those reported in their manuscript have been published elsewhere other than in abstract form and that they are not under consideration for publication elsewhere.

JAT will not tolerate misconduct including, but not limited to, data fabrication or falsification including deceptive manipulation of images and plagiarism. If any manuscript is found to contain misconduct, the review process will be halted immediately, and the University or Institute of the corresponding Author could be informed at the discretion of the editorial committee and the ethical committee of JAS.

## COI:

In accordance with the JAS Conflict of Interest Policy, the *JAT* requires all authors to disclose any financial relationship (within the past 36 months) with a biotechnology manufacturer, a pharmaceutical company or any other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. Upon submitting the manuscript, click a checkbox next to either YES or No. Prior to acceptance, the corresponding author is required to provide details regarding *all* authors' financial interests if there is anything to disclose, and the editorial staff will verify all of the disclosures described in the article. If any inaccuracy is found in the information disclosed, the editorial office will decline to publish the manuscript, or if it is already published, then the editorial office will deal with the matter in accordance with the JAS Conflict of Interest Policy.

### Copyright:

**Each author** must release first and subsidiary rights to their manuscript at the time of acceptance for publication by

forwarding dated copyright form containing signature of the author.

JAT allows others to download the material and share it (either whole or parts of it) with others without any permission as long as they credit the original source and indicate if changes were made. But they can't use the material commercially. The original source should also be included in the reference list, if any.

#### **Ethics:**

When reporting experiments on human subjects, indicate whether the procedures followed were in accord with the ethical standards of the responsible institutional or regional committee on human experimentation or in accord with the latest version of DECLARATION OF HELSINKI. Do not use patient names or initials or hospital name in the manuscript. When reporting experiments on animals, indicate whether the institution's guidelines for the care and use of laboratory animals were followed.

## **Clinical Trial Registration Number**

The JAT follows the trials registration policy of the ICMJE and recommends that authors indicate the trial registration number at the end of the abstract. The JAT also recommends that, whenever a registration number is available, authors list this number the first time they use a trial acronym to refer either to the trial they are reporting or to other trials that they mention in the manuscript.

## Categories of Manuscript:

JAT accepts following categories of articles.

Review

Original Article (Basic Research)

Original Article (Clinical Investigation)

Case Report

Editorial

Correspondence

## Preparation of Manuscript:

The authors are requested to follow the following instructions precisely so as not to delay review and handling of manuscripts.

### **Cover Letter**

A cover letter should include a statement regarding prior publication and concurrent consideration for publication.

# Organization and Typing of Manuscript

All manuscripts must be organized according to the following format: 1) **Title page**; Designate one author as corresponding author and provide his/her complete address, telephone and fax numbers, and e-mail address. 2) **COI**, 3) **Abstract** (not more than 250 words, and do not cite references in the abstract), **Key words** (3–5 words), **Running title** (not more than 40 characters), 4) **text**, 5) **Acknowledgments** and **Notice** of grant support, 6) **References**, 7) **Footnotes** to text, if any, 8) **Tables**, 9) **Figures**, and 10) **Legends for Figures**. The title page should indicate the title of paper (not more than two printed lines of about 90 characters), full name(s) of author(s) (without titles) and addresses of their institution(s), 11) **category of manuscript**.

The text of **Original Articles** should consist of **Introduction**, **Aim**, **Methods**, **Results**, **Discussion** and **Conclusion**.

Review has no fixed format; however, if the work has previously been presented at a meeting, this should be stated. The text of Case Report should contain Introduction, Case Presentation, and Discussion in sequence. Case reports should provide new information and clinical impact that enhance our knowledge on the disease pathogenesis and process, such as a novel syndrome or a genetically confirmed rare case, or should report unusual clinical or pathophysiological features that promote further study on a larger scale. Information linked to the patients' identification must be carefully masked.

Correspondence is considered for publication, subject to

editing and abridgement, provided they do not contain material that has been submitted or published elsewhere.

Correspondence should offer objective and constructive criticism of published articles in JAT. Please note the following.

- Correspondence must not exceed 1,000 words in length.
- Correspondence can have not more than ten references and one or two figures or table.
- Correspondence can be signed by not more than three authors. All manuscripts must be typed in double space on 21×29.7 cm paper with a margin of about 3 cm on each side, with each of sections 1) to 9) beginning on a separate page.

## **Units and Abbreviations**

Unit abbreviations should be without periods and in accordance with the "Style Manual for Biological Journals", 2nd Edition, prepared by the Committee on Form and Style of the Conference of Biological Editors, American Institute of Biological Science, Washington, D. C., 1976. Some examples of commonly used abbreviations are as follows; L, mL,  $\mu$ L, g,

mg,  $\mu$ g, ng, mol,  $\mu$ mol, nmol, pmol, mp, bp, h, min, s, cpm, ppm, M, mM,  $\mu$ M, nM, pM, rpm. Some abbreviations commonly used in clinical biochemistry, such as mg/dL, though not included in the Committee's manual may also be used. However, other uncommon abbreviations should be avoided or collectively spelled out in footnote of the first page of the text.

### **Figures and Legend**

It is recommended to submit figures in color so as to be appeared in color on the Web. at no additional charge.

For each figure, provide a short title and legend sufficiently detailed that the figure is intelligible without reference to the text

Histopathological images should be saved at a resolution of at least 800dpi. Figures should be numbered in the order in which they are cited in the text.

### **Tables**

Tables should be prepared so that they are self-explanatory. No vertical lines should be used to set columns apart, and horizontal lines are limited to three (between the title and the column headings, between the headings and the body and between the body and the legend or footnote). Each table should have a short title, and tables should be numbered in the order in which they are cited in the text. Tables should be typed double-spaced throughout with each table on a separate page. References to footnotes should be made using the symbols \*, \*\*, and \*\*\* (for statistical significance), and § or for other use.

### References

References cited in the text should be numbered in order of appearance as numerals in brackets and listed in the Reference section of the paper. They should be arranged as follows: all author(s) name and initials (without period), title of paper, name of journal, year of publication, volume, and first and last page numbers connected with a hyphen(-). The titles of journals should be abbreviated as shown below according to the current system for Chemical Abstract and Biological Abstract, which is in accordance with the International List of Periodical Title Word Abbreviations (International Standard ISO 833) published in November 1974 by the International Organization for standardization. References to books should include author's name(s) and initials (without period), title of article, title of book starting with "In:", edition, editor's name(s) and initials (without period), first and last pages connected with a hyphen(-) after pp, publisher, place of publication, and year of publication, as shown below for book citation.

- (1) Ballantyne C, Arroll B, and Shepherd J: Lipids and CVD management: towards a global consensus. Eur Heart J, 2005; 26:2224-2231
- (2) Messina V, Mangels R, and Messina M: Vitamins. In: The dietitian's Guide to vegetarian diets- issues and applications 2nd Ed, ed by Messina V, Mangels R and Messina M, pp170-217, Jones and Bartlett Publishers, Inc, Massachusetts, USA, 2004 (3) Lohman TG, Roche AF, and Martorell R: Anthropometric Standardization Reference Manual, Human Kinetics Books, Champaign, Illinois, 1988

## **Reproduced Figures and Tables**

Every reproduced figures and tables must have permissions from their copyright holders. Please obtain them yourselves in advance and clearly state that in their figure legends. Examples:

- (1) 'Adapted from reference xx with permission'
- (2) 'Reproduced with permission from xxxx, et al. J Atheroscler Thromb, 2013; 77: xx-xx'

# Costs to Author and Reprints:

The authors of all papers accepted for publication will be charged a fee of JPY70,000 (except bank charges and tax). All authors must be sure to pay the invoice before the advance publication.

Reprints can be purchased at the prices listed below. The order can be accepted only every 100 copies as a unit.

Delivery and bank remittance fees are not included in the list.

#of pages	100 copies	200 copies	300 copies
1–4	¥63,000	¥81,000	¥99,000
5-8	¥72,000	¥90,000	¥108,000
9–12	¥81,000	¥99,000	¥117,000
13-16	¥90,000	¥108,000	¥126,000

(Currency: Japanese Yen)

Color Reprint for Figures			
#of pages	#of Figures		
	1	¥70,000	
1	2	¥75,000	
	3	¥80,000	
	2	¥84,000	
2	3	¥89,000	
	4	¥94,000	

(Currency: Japanese Yen)

### **JAT Office Contact Information:**

The Journal of Atherosclerosis and Thrombosis is published by the Japan Atherosclerosis Society.

Manuscripts should be submitted through online system by accessing http://submit.highwire.org and other scientific correspondence should be addressed to:

JAT Editorial Office
Japan Atherosclerosis Society
Nichinai-Kaikan B1, 3-28-8 Hongo
Bunkyo-ku, Tokyo 113-0033, Japan
E-mail: jat\_office@j-athero.or.jp